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ABSTRACT 
Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant genetic 
cardiovascular disorder marked by genetic and phenotypic heterogeneity. Mutations in the gene 
encodes the cardiac myosin-binding protein C, cMYBPC3 is amongst the various sarcomeric genes 
that are associated with HCM. These mutations produce mutated mRNAs and truncated cMyBP-C 
proteins. In this review, we will discuss the implications and molecular mechanisms involved in 
MYBPC3 different mutations. Further, we will highlight the novel targets that can be developed 
into potential therapeutics for the treatment of HMC. This article is protected by copyright. All 
rights reserved 
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1 Introduction 
Hypertrophic cardiomyopathy (HCM) is an inherited autosomal dominant condition that 
occurs as a result of mutations in the gene encoding for different types of sarcomeric proteins 
(Marian et al., 2001). The main characteristic of HCM is left ventricular hypertrophy (LVH) 
associated with myocardial and myofibrillar disarray in addition to a marked increase in interstitial 
fibrosis, which occurs in the absence of secondary cardiovascular triggers (Schlossarek et al., 2011). 
HCM is the second most common form of heart muscle disease, the latter is dilated, restrictive or 
arrhythmogenic right ventricular cardiomyopathy (Cecchi et al., 2012).  
HCM can affect 1:500 from the general population (Tian et al., 2013). Approximately 
700,000 Americans are thought to be affected by HCM (Marsiglia and Pereira, 2014), while in 
Europe, the estimate exceeds one million individuals (Olivotto et al., 2013). A recent study of the 
Arab/Middle Eastern population has suggested that approximately 160,000 individuals are believed 
to be affected by HCM in the Egyptian population alone (Kassem et al., 2013).  
Advances in molecular genetics underlying the causes of HCM have led to the identification 
of mutations in 11 genes for sarcomeric proteins, predominantly the β-myosin heavy chain 
(MYH7), cardiac myosin binding protein C (MYBPC3), cardiac troponin T (TNNT2), α-
tropomyosin (TPM1), and cardiac troponin I (TNNI3) (summarized in Table 1) (Cirino and Ho, 
2014; Roma-Rodrigues and Fernandes, 2014). The disease has also been linked to mutations in one 
of the genes that encode a protein from the Z-disc or calcium handling proteins (Marsiglia and 
Pereira, 2014). 
The majority of HCM cases are generally heterozygous, although a small percentage of 
patients present with a severe form of HCM due to the compound effect of double heterogeneity or 
homogeneity (Gajendrarao et al., 2015), which usually is associated with a worsened prognosis 
(Schlossarek et al., 2011). HCM is considered a hereditary condition, as a result of almost 1,500 
individual mutations in different sarcomeric genes. HCM can exhibit remarkable genetic, 
phenotypic, and clinical heterogeneity (Maron et al., 2014).  
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The unpredictability of HCM and the incoherent genotypic-phenotypic association renders 
HCM one of the most challenging, yet seemingly common, inherited cardiac disease. Therefore, a 
better understanding of different sarcomeric gene functions and the mutations that lead to HCM is 
critical in order to identify their potential clinical and therapeutic importance. This review discusses 
the implications of MYBPC3 in HCM and highlights the most recent areas of research in which 
mutations in MYBPC3 have proven valuable in the understanding of the disease mechanism and 
potential therapeutic opportunities. 
2 The cardiac myosin binding protein C structure (cMyBP-C) 
Myosin binding protein C (C-protein) is present in 3 isoforms encoded by the skeletal 
MYBPC1 & MYBPC2 and the cardiac MYBPC3 genes (Barefield and Sadayappan, 2010; Lin et 
al., 2013). The MYBPC3 cDNA (3.7 kpb) is composed of 35 exons, while the total length of the 
MYBPC3 gene is about 21 kbp (Figure 1a) (Behrens-Gawlik et al., 2014). The cMyBP-C consists 
of 7 immunoglobulin (IgI) domains, 3 fibronectin type III (FnIII) domains (C1-10), a 105-residue 
region between C1-C2 referred to as MyBP-C motif, and a prolin/alanine-rich (PA) region near the 
N-terminus (Figure 1b) (Barefield and Sadayappan, 2010). In addition to Ig domain (C0) at the N-
terminus and 3 phosphorylation sites in the β-sheets rich MyBP-C motif, the domain C5 carries an 
added proline- rich 25 residue insertion (Luther and Vydyanath, 2011). Fluorescence, NMR and 
mass spectrometry techniques have provided evidence for the involvement of the C-terminal with 
the anchoring of the cMyBP-C with the thick filament (Finley and Cuperman, 2014), while the N-
terminal is thought to interact mainly with actin and myosin in addition to allowing the MyBP-C 
motif to bind with myofilament-associated proteins (Finley and Cuperman, 2014).  
Lu et al. have demonstrated that the C0 and C1 domains of the N-terminal can interact with 
both the S2 region of myosin and actin through a set of common binding bases, thereby postulating 
a phosphorylation-independent switching mechanism that allows the cMyBP-C to alternate between 
actin and myosin (Lu et al., 2011). In addition, it was shown that both calcium (Ca
2+
) and 
calmodulin can interact with the C1C2 domains through a phosphorylation-independent manner 
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facilitated by the MyBP-C motif (Lu et al., 2012). On the contrary, others have discussed that the 
MyBP-C motif is thought to aid in the cMyBP-C/myosin S2 interaction in a phosphorylation-
dependent manner (Figure 2) (Previs et al., 2012). In a recent study, Rybakova et al.indicated that 
cMyBP-C fragments lacking the N-terminal domains C0-C4 bonded with F-actin in an essentially 
similar manner to the full-length protein, suggesting that no apparent interaction of the N-terminal 
domains occurs with F-actin, and that the C-terminal end domains, C5-C10, bind to F-actin with 
high affinity (Rybakova et al., 2011). In spite of the controversy surrounding binding of actin to the 
C2 domain of cMyBP-C, it has been well established that the C-terminal end is critical for its 
interaction with the of myosin as well as titin (Behrens-Gawlik et al., 2014; Finley and Cuperman, 
2014; Schlossarek et al., 2011; Sequeira et al., 2014), an association that appears to be critical for 
the cMyBP-C stability and sarcomere organization (Barefield and Sadayappan, 2010). 
The cMyBP-C is thought to be involved in filament assembly and the regulation of cardiac 
muscle contractility via modification of the actin-myosin association as demonstrated by several 
recent studies (Finley and Cuperman, 2014; Luther and Vydyanath, 2011). Initially, it was thought 
that during β-adrenergic stimulation, the MyBP-C motif undergoes phosphorylation, thereby 
releasing the bound myosin S2 domain and accelerating the cross-bridge cycling rates and force 
generated (Finley and Cuperman, 2014). In contrast, data from constructs of cMyBP-C containing 
the MyBP-C motif suggest that calmodulin may serve as a structural conduit linking cMyBP-C with 
Ca
2+
 signaling pathways, thus aiding in the coordination of phosphorylation events and 
orchestrating different interactions between cMyBP-C, myosin, and actin during the process of 
cardiac muscle contraction (Lu et al., 2012). Phosphorylation of the cMyBP-C by the 
Ca
2+
/ almodulin kinase II (CaMKII), protein kinase A (PKA) and protein kinase C (PKC) has been 
suggested to be essential for the regulation of actin-myosin association and sarcomeric contractility 
(Barefield and Sadayappan, 2010). A reduction in the phosphorylation of c-MyBP-C, however, is 
thought to degrade the protein and has been modeled in a number of patients presenting with HCM 
(Copeland et al., 2010; van Dijk et al., 2009).  
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The evidence presented highlights the importance of c-MyBP-C phosphorylation for normal 
cardiac function and suggests that lower protein phosphorylation could appear to be a common 
feature for the clinical HCM phenotype. Moreover, a recent study involving bioinformatics 
molecular modeling has suggested that disease-causing mutations Arg177His, Ala216Thr and 
Glu258Lys (Kassem et al., 2013) can affect the structural properties of the protein’s C1 domain, 
thus altering its structural integrity and interaction with both actin and myosin (Gajendrarao et al., 
2013). This association between the structural integrity of c-MyBP-C and the different molecular 
mechanisms affected is critical for adequately defining the phenotype of HCM. Further studies are 
necessary in order to accelerate the current molecular understanding of the structure of the cMyBP-
C in order to uncover the variable disease phenotypes and prognoses with different MYBPC3 gene 
mutations (Lu et al., 2012). 
 
3 MYBPC3 Mutations in Hypertrophic Cardiomyopathy 
Mutations in 11 different sarcomeric genes account for HCM, up to 40% of which have 
been mapped to the MYBPC3 gene (Behrens-Gawlik et al., 2014). Nearly 197 HCM mutations 
have been identified in MYBPC3 ranging from missense mutations, nonsense mutations, splice site 
donor/acceptor mutations, insertions, and deletions (Mamidi et al., 2013; Vignier et al., 2009). 
However, ~57% of the established mutations occur as insertions and deletions, which contributes to 
the production of frameshift and null alleles while the remaining ~43% carry nonsense mutations 
(Sequeira et al., 2014). These mutations lead to the generation of a premature termination codon 
(PTC)-bearing mRNAs, which have been shown to produce truncated cMyBP-C proteins lacking 
the myosin and/or titin binding sites (Behrens-Gawlik et al., 2014; Schlossarek et al., 2011), binding 
domains involved in targeting cMyBP-C to the thick filament. On the other hand, missense alleles 
can lead to the production of dominant negative stable poison peptides, which, when incorporated 
into myosin filaments, can hinder the normal mechanical functions of the sarcomere and disrupt the 
electrophysiological properties of myocytes (Tian et al., 2013).  
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Two major quality control systems are thought to be responsible for minimizing mutant 
MYBPC3 and contributing to low levels of mutated cMyBP-C protein, the non-mediated mRNA 
decay (NMD) and ubiquitin-proteasome system (UPS) systems (Figure 3) (Schlossarek et al., 
2011). At the mRNA level, the NMD system has been shown to become active in mouse models of 
HCM expressing mutant MYBPC3 (Marston et al., 2012). The NMD appears to target PTC-
containing transcripts and swiftly degrade them, thereby protecting its host from the deleterious 
effects of any C-terminal truncated proteins that may have been generated (Carrier et al., 2010). On 
the protein level, the UPS, a form proteolysis that is highly specific and selective to the degradation 
of cytosolic, nuclear and myofibrillar proteins (Schlossarek et al., 2013), protects against the 
production of poison peptides (Behrens-Gawlik et al., 2014; Carrier et al., 2010; Vignier et al., 
2009). Preventing the accumulation of damaged, misfolded and mutant proteins is one of the main 
functions of the UPS (Carrier et al., 2010; Schlossarek et al., 2012a). Therefore, degradation of 
truncated proteins through the NMD and/or UPS is crucial to effectively eliminate mutant proteins 
and avoid the resultant insufficiency in full-length, functional cMyBP-C, which is considered the 
basis for haploinsufficiency in HCM. 
Over the last ten years, several mouse models have been designed to specifically determine 
whether the ablation of MYBPC3 or minute levels of truncated cMyBP-C (haploinsufficiency) were 
responsible for the induction of HCM and how MYBPC3 mutations contribute to the pathogenesis 
of this disease (Barefield and Sadayappan, 2010). In an HCM model of MYBPC3 knock-in (KI) 
mice, cardiac dysfunction and interstitial fibrosis accompanying eccentric LVH was associated with 
a significant reduction in MYBPC3, in the absence of truncated cMyBP-C (Stohr et al., 2013; 
Vignier et al., 2009). However, recent studies have strongly indicated that haploinsufficiency 
(Marston et al., 2012) serves as a key pathogenic determinant of HCM in both patients and animal 
models (Behrens-Gawlik et al., 2014; Schlossarek et al., 2011). Using the HCM model of MYBPC3 
(KI) mice carrying a point mutation, Vignier et al. demonstrated a 90% haploinsufficiency in the KI 
mice, as well as a 21% in the heterozygous (HET-KI) breed (Vignier et al., 2009). In patients with 
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known HCM-causing MYBPC3 mutations, van Dijk et al. also identified haploinsufficiency 
associated with deranged contractile protein phosphorylation, as the culprit of reduced cardiac 
contractility (van Dijk et al., 2009; Vignier et al., 2009). Interestingly, in a later study, the authors 
demonstrated that despite the higher myofilament Ca
2+
 sensitivity detected in the MYBPC3 mutant 
carriers, there were no significant differences between the phosphorylation states of cMyBP-C in 
mutant carriers and non-failing donors (van Dijk et al., 2012). Whether the altered state of the 
sarcomeric function is attributed to hypophosphorylation-induced Ca
2+
 hypersensitivity, or 
enhanced Ca
2+
 sensitivity regardless of the phosphorylation state of the cMyBP-C is yet to be 
determined. Nevertheless, the evidence presented seems to indicate that haploinsufficiency in 
HCM-associated MYBPC3 mutations increases Ca
2+
 sensitivity and thus alters sarcomeric cardiac 
contractility. 
Familial HCM patients with MYBPC3 frameshift mutations had a reduced cMyBP-C 
protein level and a contractile dysfunction supporting that the patho-mechanism involves 
haploinsufficiency rather than a poison peptide. In addition, mutant cMyBP-C mRNA levels were 
lower than the WT mRNA, suggesting that degradation of the mutant mRNA might be through the 
NMD (van Dijk et al., 2009). This study is consistent with that of Marston et al. which found that 
HCM patients with missense mutation and premature termination in domain C3 had no detectable 
truncated MyBP-C protein, arguing strongly that haploinsufficiency, as the HCM mechanism, and a 
reduction in mutant mRNA are possibly caused by NMD (Marston et al., 2009) On the basis of the 
former data, the UPS system could act as parallel quality control systems with the NMD to 
eliminate mutant cMyBP-C mRNA and protein (Marston et al., 2009; van Dijk et al., 2009; van 
Dijk et al., 2012).  
A dysfunction in the UPS has also been suggested to underlie the pathogenesis of HCM and 
the degradation of truncated cMyBP-C protein. Sarikas et al. had indicated that truncated cMyBP-C 
protein was rapidly degraded by the UPS in neonatal rat cardiac myocytes transfected with human 
truncated cMyBP-C mutants. Additionally, truncated cMyBP-C mutant M7t resulted in the 
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formation of ubiquitin-positive aggregates that impaired the function of the UPS system (Sarikas et 
al., 2005). Schlossarek et al. have demonstrated that both KI and KO mice models exhibited low 
levels of mutant cMyBP-C protein due to their degradation via the UPS. A1-year-old HCM mouse 
KI model exhibited a UPS impairment (Schlossarek et al., 2012a).  
The exact mechanism through which UPS dysfunction occurs during HCM has been 
attributed to the saturation of the UPS following the chronic degradation of mutant cMyBP-C, 
which appeared to be the case in adult MYBPC3 KI mice (Schlossarek et al., 2012a). Coupled with 
external stress, such as adrenergic stimulation, the altered cardiac phenotype in MYBPC3-KI mice 
could also exacerbate the impairment of the UPS (Schlossarek et al., 2013). It has also been 
suggested that mutant cMyBP-C competes with other factors for UPS-mediated degradation, such 
as the hypertrophic transcription factor GATA4 or the anti-apoptotic factor p35, thus contributing to 
the pathogenesis of HCM (Carrier et al., 2010).  
In cardiomyocytes, the UPS impairment has also been shown to contribute to the 
pathophysiology of HCM (Schlossarek et al., 2012b). UPS impairment could result in increased 
levels of pro-hypertrophic and pro-apoptotic factors, accumulation of unfolded or misfolded 
proteins resulting in ER stress and alterations of Ca
2+
 handling as shown in an in vitro model of 
missense MYBPC3 mutation and in patients with adult-onset HCM, leading to cardiac dysfunction 
(Schlossarek et al., 2013). Interestingly, expression of the missense MYBPC3 mutant protein in 
cells led to a significant reduction in proteasome activity, indicating UPS impairment, and 
significantly increased the proapoptotic/antiapoptotic protein ratio, enhancing apoptosis (Bahrudin 
et al., 2008). Similarly, the novel missense MYBPC3 mutation E334K detected in Japanese patients 
induced proteo-toxicity and severe cardiac hypertrophy through a dysfunction in the UPS. E334K 
mutant cMyBP-C stable transfectants Cos-7 cells showed a decreased level of 20 S proteasome 
activity, increased ratio of proapoptotic/antiapoptotic regulating protein, increased apoptosis and 
consequent accumulation of truncated cMyBP-C protein  (Bahrudin et al., 2008). Even though 
levels of truncated cMyBP-C are virtually undetectable in HCM patients, the incorporation of 
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truncated protein into the sarcomere could dysregulate sarcomeric function and promote myocyte 
hypertrophy (Olivotto et al., 2012), suggesting that the “poison peptide” mechanism could actually 
worsen the HCM phenotype when the UPS is impaired. Nevertheless, further studies are necessary 
in order to determine whether targeting the UPS could serve as a potential treatment for HCM. 
 In cardiac dysfunction, the alterations of the UPS and the autophagy-lysosyme pathway 
(ALP) that regulates autophagy suggests that UPS proteolytic function can become inadequate or 
impaired following severe cellular stress (Zheng and Wang, 2010). Under this circumstance ALP 
may be increasingly activated to help ameliorate the cellular stress. Autophagy plays a dual role in 
the pathogenesis of cardiac diseases. Autophagy is activated to protect cells against cellular stress, 
while excessive autophagy promotes cell death (Zheng and Wang, 2010). Nakai A et al. found that 
inhibition of autophagy by autophagy-related 5 protein Atg5 knockdown induced morphological 
and biochemical features of cardiomyocyte hypertrophy (Nakai et al., 2007), suggesting a role for 
the ALP system in heart disease. 
Although the general assumption is that the UPS and ALP systems act separately, it was 
found that various proteins, including p62, NBR1, HDAC6, and co-chaperones, play an important 
role in synchronizing the consortium formed by the UPS and ALP systems to remove mutant 
cMyBP-C in HCM (Zheng and Wang, 2010). In fact, genetically engineered HCM KI mouse model 
showed UPS impairment, reduced belcin-1 degradation, and reduced lysosomal-mediated LC3 
degradation leading to ALP impairment as a common disease mechanism. Schlossarek et al. 
attributed this impairment to the obstruction of the fusion occurring between autophagosome and 
lysosome, which thereby inhibits the development of the autophagolysosome and subsequent 
degradation of the autophagosome product (Schlossarek et al., 2012a). Additionally, Cao et al. 
supported that autophagy plays an important role in the regression of cardiac hypertrophy and that 
FoxO family proteins are critical regulators of autophagy after unloading the hypertrophic stimuli 
(Cao et al., 2013).  
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In order to develop novel and effective therapeutics for cardiac hypertrophy, it is necessary 
to identify the cellular and molecular mechanisms underlying regression.  Regression of cardiac 
hypertrophy could be induced by the down-regulation of protein synthesis or the up-regulation of 
protein degradation. 
 
4 Molecular modeling of HCM-causing mutations  
Studying the structure-function relationships of cMyBP-C is extremely useful for 
understanding the pathogenesis of HCM. Determination of the 3D data of c-MyBP-C has been 
challenging for structural studies such as X-ray crystallography and NMR for decades due to the 
conformational plasticity of the protein. As a result, only 5 domain structures have been determined 
[C0 (Ratti et al., 2011), C1 (Ababou et al., 2008; Fisher et al., 2008; Ratti et al., 2011), C2 (Govada 
et al., 2008), C3 (Ababou et al., 2007) and C5 (Zhang et al., 2014)] out of 11 domains of cMyBP-C. 
Molecular modeling is an effective tool to model 3D structures of the protein, and it has been used 
to model HCM-causing mutations to study their structural consequences (Idowu et al., 2003). 
Molecular dynamics simulation is one of the advanced techniques in modeling, which can provide a 
dynamical behavior (stability, energy, and interactions) of molecular systems.   
Recently, mutational modeling studies have been carried out on cMyBP-C in domain C1 
(Gajendrarao et al., 2013)  and in a molecular complex of domains C1-motif-C2 (Gajendrarao et al., 
2015). In the C1 study, three disease-causing mutations (found in Egypt and Italy) were modeled 
(Figure 4). It provided possible explanations for the initiation of the malfunction of the protein at 
the molecular level from C1 and potential interference of cMyBP-C binding with actin and myosin. 
Interestingly, it was reported that these three mutations follow different mechanisms to affect the 
structural integrity of the domain C1. However, this study requires further experimental validations. 
In the study of C1-motif-C2, double mutations (E258K and E441K from domains C1 and C2, 
respectively) were studied in a patient with severe end-stage HCM phenotype (Gajendrarao et al., 
2015). This is the first study to represent a full-length 3D model of the c-MyBP-C motif (Figure 
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4a), which was modeled from a partial structure of motif from mouse (Howarth et al., 2012). It also 
presented a complex model of C1-motif-C2. This study described the fact that the double mutations 
in isolation can predominantly affect the native domain and the nearby motif via conformational 
changes, resulting in an additive effect when they coexist.  
The molecular changes described in the modeling studies propose that it could distract binding of 
the cMyBP-C molecule to actin or myosin and thus interfere with both contractile and electrical 
functions. These molecular events can be responsible for at least some of the pathological changes 
observed in HCM. Although the modeling studies of cMyBp-C can prioritize essential models for 
understating the molecular mechanisms of HCM, it requires experimental support from bio-
molecular and animal studies to progress towards designing potential drugs for treating HCM.  
 
5 Models of MYBPC3 mutations 
With the remarkable opportunities provided by the availability of human heart tissue 
samples come inevitable limitations, including the variable methods of sample collection, the 
heterogeneity of clinical characteristics, and restricted time frames in the course of diseases. These 
factors are important to recognize and acknowledge when interpreting data from such studies, and 
they highlight the importance of developing animal models as a means to further understand the 
pathogenesis of HCM (Day, 2013). 
One of the valuable models of MYBPC3-induced HCM is the MYBPC3 KI mice initially 
developed by Vignier et al. Both homozygotes (KI) and HET-KI mice carried a single nucleotide 
transition at exon 6. Only the homozygotes KI mice expressed the missense mRNA and nonsense 
mRNA in the urea fraction of the protein and developed the overt-HCM phenotype. This alteration 
between both lines suggests an impairment of the NMD and a saturation of the UPS (Vignier et al., 
2009). Furthermore, both lines exhibited impairment of both UPS and ALP activation. Both 
proteolytic systems would be responsible for minimizing mutant MYBPC3 mRNA and mutated 
cMyBP-C protein as the general pathology associated with the marked cardiac hypertrophy 
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presented by MYBPC3 KI and KO genetically-engineered cardiomyopathic mice (Schlossarek et 
al., 2012a). 
Although in mice models of HCM, the homozygous line tends to display a cardiac 
hypertrophic phenotype, in human patients, the phenotype is typically heterogeneous (Olivotto et 
al., 2012; Schlossarek et al., 2012a; Schlossarek et al., 2012b; Vignier et al., 2009). Barefield et al. 
have demonstrated that in an HCM model of heterozygous KI MYBPC3 truncation mutation (HET 
+/t
), the HET 
+/t
 mice developed diastolic dysfunction, as indicated by a reduced maximal force 
generation of skinned cardiomyocytes and altered cardiac function (Barefield et al., 2014). 
However, when compared to WT mice, the HET 
+/t
 mice did not express an apparent hypertrophic 
phenotype and preserved cMyBP-C levels (Barefield et al., 2014).  
To further examine whether hemodynamic stress could unmask a cardiac hypertrophic 
phenotype in the heterozygous MYBPC3 KI mice (HET-KI), Schlossarek et al. investigated 
morphological changes to the heart in HET-KI mice exposed to adrenergic stimulation. When 
compared to the heterozygous MYBPC3 KO mice (HET-KO), HET-KI mice treated with a 
combination of isoprenaline and phenylephrine for 1 week exhibited significant septal hypertrophy 
as well as a UPS impairment, suggesting that the HET-KI model can mimic the genetic profile of 
HCM patients carrying only one mutant MYBPC3 allele (Schlossarek et al., 2012b).  
In a more recent study, Barefield et al. investigated the effects of inducing cardiac stress on 
the impact of hypertrophic remodeling in HET mice carrying an MYBPC3 truncating mutation 
(Barefield et al., 2015). The study revealed that systolic function, ejection fraction and cMyBP-C 
levels and were significantly reduced following transverse aortic constriction-induced pressure 
overload indicating that HET mice exposed to cardiac stress develop a magnified HCM phenotype 
compared to WT controls (Barefield et al., 2015). These findings stromgly indicate that while 
heterozygous MYBPC3 mutant carriers may appear asymptomatic, they suffer functional 
impairment on single cardiomyocyte and whole heart levels, an effect that is exacerbated and leads 
to an overt HCM phenotype upon hemodynamic and cardiac stress.  
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In order to verify the phenotypes observed in both HET-KI and homozygous MYBPC3 KI 
mice, Stöhr et al. generated engineered heart tissue (EHT) (Stohr et al., 2013; Wijnker et al., 2016) 
derived from the genetically defined and characterized mouse model of HCM (Vignier et al., 2009). 
This model appears to be more reliable than tissue samples extracted from animal models or HCM 
patients since some of the pathophysiological defects associated with MYBPC3 mutations may be 
secondary changes in response to treatment protocols of HCM patients or even the experimental 
protocol used to induce HCM disease model (Wijnker et al., 2016). Although the ability of EHTs to 
exhibit a disease phenotype was questionable, both models showed definite functional 
abnormalities, with marked differences in the sensitivity to external Ca
2+
 concentrations and the 
contractile response to drugs. These results highlight the importance of using induced pluripotent 
stem cell (iPSC) mediated disease modeling of human HCM to shed light on potential therapeutic 
targets for a more personalized approach to therapy. 
The use of iPSC-mediated disease modeling of human HCM was recently demonstrated by 
Ojala et al. using HCM cardiomyocytes isolated from patient-specific human induced pluripotent 
stem cells (hiPSCs) (Ojala et al., 2016). hiPSCs carrying either a MYBPC3 (MYBPC3-Gln1061X) 
or α-tropomyosin (TPM1-Asp175Asn) mutation were examined for differences in Ca2+ handling, 
gene expression profiles, cellular size and electrophysiological properties. While the hiPSCs 
demonstrated a similar pathological phenotype of HCM, the results clearly indicated differences in 
cellular enlargement between the two HCM mutations, as well as Ca
2+ 
sensitivity and 
arrhythmogenic events (Ojala et al., 2016). Taken together, the studies exploiting the use of iPSC-
derived cell models, provide novel means to further understand the pathophysiological mechanisms 
of HCM and to possibly personalize the current treatments in mutation-specific direction. 
In order to differentiate between the functional and structural phenotypes of cMyBP-C 
ablation, Chen et al. developed a tamoxifen-inducible cMyBP-C conditional knockout (cMyBP-C-
cKO) mouse model of HCM. Using this approach, the authors were able to acutely abolish cMyBP-
C expression in the myocardium of 12-week-old cMyBP-C-cKO mice, showing that cardiac 
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dysfunction preceded both LV dilation and cardiac hypertrophy in the cMyBP-C-cKO mice. Once 
subjected to transaortic constriction, the model developed progressive LV dilation and further LV 
hypertrophy. These findings demonstrate that in reality additional factors such as hemodynamic 
stress can entail the clinical expression of HCM (Chen et al., 2012).  
In the precipitation of systolic and diastolic dysfunction in MYBPC3-associated HCM, little 
is known. Vignier et al. sought to investigate the involvement of the renin-angiotensin system in the 
heterozygous MYBPC3 KO mouse (HET-KO) model of HCM. Concurrent with the development of 
LV hypertrophy, ACE-1 gene expression appeared to be significantly elevated in HET-KO mice 
than in WT mice. Interestingly, both angiotensin II type 1 receptor (Agtr1) and MYPC3 gene 
expression were significantly increased in HET-KO mice treated with Agtr1 blocker irbesartan, 
revealing that FH1 (four-and-a-half LIM domains) is a regulator of cMyBP-C activity and is 
involved in the sarcomere assembly. These results suggest a predominant role for the renin-
angiotensin system and FH1 in MYBPC3-mediated HCM, thus highlighting a potential therapeutic 
target that could prevent the development of LV hypertrophy and the progression of HCM (Vignier 
et al., 2014). 
A major concern of using the rodent model of HCM is the vast differences in the 
presentation of HCM and sarcomeric proteins in rodents compared to humans (Chen et al., 2013; 
Marian et al., 2001). Such variations could even limit the use of transgenic rodent models to 
decipher the pathogenesis of HCM in humans. Zebrafish (Danio rerio), a tropical freshwater fish, 
has recently emerged as an ideal vertebrate animal system for investigating mechanisms of cardiac 
development and human CHDs (Poon and Brand, 2013). The ability of zebrafish mutant embryos to 
survive without a functional circulation system for several days further emphasizes the feasibility of 
carrying out gain-of-function and loss-of-function studies in zebrafish (Yang et al., 2014). 
Chen et al. recently established the first model of MYBPC3 knockdown-induced cardiac 
hypertrophy and diastolic heart failure in zebrafish. The authors confirmed a sequence homology 
between human and zebrafish MYBPC3 and demonstrated that at 72 hpf, morpholino-mediated loss 
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of MYBPC3 induces ventricular wall thickening and the expression of hypertrophic sarcomeric 
proteins and cardiac myosin light chain 2, features that closely resemble human ventricular 
hypertrophy and HCM (Chen et al., 2013). The knockdown of the MYBPC3 in zebrafish showed 
LVH and contractile dysfunction; interestingly, that was also observed in FHCM patients carrying 
the MYBPC3 mutation (van Dijk et al., 2009).  
Hodatsu et al. recently recapitulated the MYBPC3 mutations of HCM patients in a zebrafish model. 
The authors concluded that double MYBPC3 mutation (Arg815Gln and Ala745Asp) could lead to a 
worsened HCM phenotype, as indicated by the significantly elevated ventricular dimensions and 
heart rate. Interestingly, the phenotype/genotype association in the zebrafish model was exacerbated 
when compared to human carriers of young age, suggesting that the zebrafish model can provide a 
valuable insight into the clinical presentation of HCM prior to its overt onset in human carriers 
(Hodatsu et al., 2014).  
 
6 Potential Therapeutic Targets for MYBPC3-associated HCM 
The current therapeutic options for HCM revolve around the use of pharmacological agents 
or surgical interventions for symptomatic relief and the prevention of SCD (Schlossarek et al., 
2011). However, these approaches fail to address the sarcomeric gene mutations. Recent studies 
have demonstrated that targeted mutated gene and RNA-based therapies could become realistic 
options for the treatment of HCM (Figure 5). Mearini et al. have revealed that the single dose 
administration of adeno-associated virus (AAV9) with the full-length MYBPC3 prevented the 
disease phenotype in the KI mice. At 34 weeks, KI treated mice had increased Mypbc3 mRNA and 
cMyBP-C protein and suppressed the accumulation of the mutant mRNA (Mearini et al., 2014). The 
phenotype difference between homozygous and het MYBPC3-KI mice supported the fact that the 
full-length (semi-functional) protein acted as a compensatory mechanism in an attempt to prevent 
cardiac dysfunction and protect against LVH (Vignier et al., 2009).  
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Gedicke-Hornung et al. demonstrated that cardiomyopathy was rescued through U7snRNA-
mediated exon skipping. This approach was evaluated for that first time for cardiac diseases. 
Antisense oligoribonucleotides significantly reduce aberrant MYBPC3 in vivo in the MYBPC3-KI 
mice and in vitro in the transfected neonatal mouse cardiac myocytes. Despite the promising results 
observed, the therapeutic effects were only transient, lasting only 48 hours in cardiomyocytes and 
55 days in newborn KI mice (Gedicke-Hornung et al., 2013; Vignier et al., 2009). Consequently, 
the 5’-trans-splicing strategy was sought out by Mearini et al. as an alternative approach to correct 
MYBPC3-associated HCM. The induction of 5’-trans-splicing between the mutant endogenous 
MYBPC3 pre-mRNA and an engineered pre-trans-splicing molecule (PTM) carrying WT MYBPC3 
cDNA in the MYBPC3-KI mice significantly repaired the cMyBP-C protein and mediated its 
successful incorporation into the sarcomere, both in cardiomyocytes and in the  MYBPC3-KI mice 
hearts (Mearini et al., 2013). These studies highlighted some of the novel gene and pre-mRNA 
based therapeutic options currently under investigation for the treatment of MYBPC3-associated 
HCM. 
Since it remains somewhat unclear whether functional phenotypes in these mice reflect 
primary responses of the heart caused by removal of cMyBP-C or secondary responses of the heart 
caused by activation of compensatory mechanisms after the removal of cMyBP-C, further studies 
are necessary in order to determine the early changes that occur specifically in response to loss of 
MYBPC3 as demonstrated by the Chen et al. Thus, understanding the changes that occur in 
response to the loss or mutation of MYBPC3 will serve as a breakthrough, as it will provide bases 
to determine whether the direct loss of MYBPC3 drives the cardiac functional abnormalities 
observed in MYBPC3 KO or whether the development of cardiac hypertrophy and LV dilation 
induces diastolic and systolic dysfunction. 
 
7 Conclusion 
The necessity of cMyBP-C for normal cardiac physiology is shown by its involvement as a key 
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regulator of contraction and relaxation in both healthy and diseased hearts. Recent studies using 
different animal models have clearly demonstrated that mutations in the MYBPC3 gene are one of 
the most frequent triggers of HCM. The involvement of the NMD, UPS and possibly, the ALP as 
different quality control systems that could be acting independently or conjointly in an attempt to 
eliminate or reduce the amount of mutant cMyBP-C have also been shown. Yet despite the 
application of genome-wide association studies technology, the exact mechanism leading to the 
manifestation of the HCM phenotype is still somewhat poorly understood. Developing new models 
using HCM-iPSC; whether EHTs or cardiomyocytes, appears to advance the high-throughput 
investigation of the pathophysiological mechanisms and potential molecular therapy for MYBPC3-
induced HCM. The understanding of detailed mechanisms underlying this inherited autosomal 
dominant condition, new therapeutic targets will definitely uncover in the not-too-distant future. 
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Table 1 
Most frequently occurring hypertrophic cardiomyopathy-associated proteins, genes and number of 
mutations described for each gene [adapted from (Cirino and Ho, 2014; Marsiglia and Pereira, 
2014)] 
 
Gene  Protein  
 
Frequency  
 
 
Myofilament genes 
  
MYH7  β-myosin heavy chain  15-25% 
MYL2  Myosin regulatory light chain  <2% 
MYL3  Myosin essential light chain  <1% 
MYBPC3  Myosin binding protein C  15-25% 
TNNT2  Troponin T  <5% 
TNNI3  Troponin I  <5% 
TPM1  α-tropomyosin  <5% 
ACTC  Alpha actin cardiac  <1% 
TNNC1  
 
Troponin C  <1% 
Z-Disc genes   
CSRP3  Muscular LIM protein  <1% 
TCAP  Telethonin  <1% 
ACTN2  α-actin  <1% 
MYOZ2  Myozenin  <1% 
NEXN  
 
Nexilin  <1% 
Calcium handling genes     
CACNA1C Calcium Voltage-Gated Channel Subunit Alpha1 C <1% 
PLN  Phospholamban  <1% 
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